Category: BioTech

BioTech

Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 8.88 percent to $13.85 yesterday on volume of 483,342million shares. The intra-day range of the stock was $12.61 to $13.95. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $203.70million. Emergent Biosolutions … Continue reading Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

John Meady
BioTech

Biotech Top Gainers: Northwest Biotherapeutics (NASDAQ:NWBO), Alexion Pharmaceuticals (NASDAQ:ALXN), Merrimack Pharmaceuticals (NASDAQ:MACK), Enzon Pharmaceuticals (NASDAQ:ENZN)

German health regulators have granted Northwest Biotherapeutics Inc (NASDAQ:NWBO) special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small US biotechnology company has not yet completed its late-stage trial of the immunotherapy. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 29.55% in last session and finished the day at $7.85. Traded volume was 6,155,092 million shares in the last … Continue reading Biotech Top Gainers: Northwest Biotherapeutics (NASDAQ:NWBO), Alexion Pharmaceuticals (NASDAQ:ALXN), Merrimack Pharmaceuticals (NASDAQ:MACK), Enzon Pharmaceuticals (NASDAQ:ENZN)

Richard Atkins
BioTech

Healthcare Bullish Stocks: Agios Pharmaceuticals (NASDAQ:AGIO), Rockwell Medical (NASDAQ:RMTI), OHR Pharmaceutical (NASDAQ:OHRP), Emergent Biosolutions (NYSE:EBS)

Agios Pharmaceuticals Inc (NASDAQ:AGIO) SVP Glenn Goddard sold 17,468 shares of the stock on the open market in a transaction that occurred on Friday, March 7th. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 13.82 % in last session and finished the day at $ 45.45. Traded volume was 1,334,731 million shares in the last session and the average volume of the stock remained 283.01 million … Continue reading Healthcare Bullish Stocks: Agios Pharmaceuticals (NASDAQ:AGIO), Rockwell Medical (NASDAQ:RMTI), OHR Pharmaceutical (NASDAQ:OHRP), Emergent Biosolutions (NYSE:EBS)

Mark Doerr
BioTech

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), CEL-SCI (NYSEMKT:CVM), Inovio Pharmaceuticals (NYSEMKT:INO)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares declined 1.14% to $8.65. The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -2.87% in last session and finished the day at $8.13. Traded volume was 13.50million shares in the last session and the average volume … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), CEL-SCI (NYSEMKT:CVM), Inovio Pharmaceuticals (NYSEMKT:INO)

Jason Knox
BioTech

Is InterMune (NASDAQ:ITMN) a Takeover Candidate?

InterMune (NASDAQ:ITMN) March 34 and 35 calls are active on total call volume 3,100 contracts (500 puts) on attracting takeover interest, Reuters says. March call option implied volatility is at 90, April is at 88, May and July is at 82; compared to its 26-week average of 90 according to Track Data. Active call volume suggests traders taking positions for price movement, according to theflyonthewall.com. … Continue reading Is InterMune (NASDAQ:ITMN) a Takeover Candidate?

Ryan Holtz
BioTech

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume was 4.36million shares in the last session and the average … Continue reading Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Mark Doerr